Deck Bio

Deck Bio, Inc. is a private, early-stage biotechnology company headquartered in Cambridge, Massachusetts, operating out of LabCentral's Kendall Square facility. Founded by CEO Jack Silberstein, the company is pioneering T cell receptor (TCR)-based therapeutics targeting intracellular cancer antigens presented as peptide-MHC (pMHC) complexes on solid tumors. Deck Bio's proprietary platform enables multi-target recognition with a single drug, designed to yield higher response rates and reduce drug resistance compared to conventional single-target approaches. By targeting highly expressed, cancer-specific peptide-MHCs, the company aims to deliver superior developability, enhanced safety, and broad patient coverage. Its lead asset, DBXO-1, is currently in preclinical development. The company is actively operating as an independent entity and received LabCentral Golden Ticket awards sponsored by both Servier and Bristol Myers Squibb.